Ruxolitinib Cream Reduced Skin Graft-Versus-Host Symptoms
A topical treatment showed promise in reducing affected skin areas for patients with chronic graft-versus-host disease.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe developing topical alternatives to standard steroids is important for chronic disease management?
In a clinical trial conducted between 2019 and 2022, ruxolitinib cream helped manage skin symptoms in patients with chronic graft-versus-host disease. This condition often results from complications following a stem cell transplant.
Why it matters
Topical corticosteroids are currently used for skin symptoms but carry risks like skin atrophy and infection. Ruxolitinib offers a potential alternative that may reduce the surface area of affected skin without these specific side effects.
This clinical trial of 24 patients evaluated the efficacy of 1.5% ruxolitinib cream compared to a placebo vehicle. By day 14, participants using ruxolitinib saw their mean affected body surface area drop to 7.7%, compared to 10.4% in the control areas.
The players
Memorial Sloan Kettering Cancer Center
A comprehensive cancer treatment and research institution where the clinical trial was conducted.
The details
Ruxolitinib is a JAK inhibitor, a class of medication that works by blocking signaling pathways involved in inflammation. In this trial, the cream was applied twice daily to the skin, where it aimed to calm the immune response that drives chronic graft-versus-host disease. By targeting this pathway directly at the site of the skin inflammation, the treatment avoided systemic side effects and the thinning of skin typically associated with long-term topical corticosteroid use.
Timeline
June 28, 2019 to September 8, 2022: Patient enrollment and randomization occurred.
Day 0: Patients discontinued previous topical therapies.
Day 14: Researchers assessed body surface area and clinical scores.
Day 28: The final treatment assessment and primary end point were recorded.
Health Landscape
This study sits within the broader research efforts at Memorial Sloan Kettering Cancer Center to identify targeted therapies for post-transplant complications. It represents an evolution from older, less-specific treatments toward localized molecular inhibition.
If you or a loved one are managing chronic graft-versus-host disease, discuss current management strategies with your hematologist or oncologist. It is important to ask about the potential for localized versus systemic treatments to minimize side effects like skin thinning.
The takeaway
This preliminary study suggests that targeting inflammation with ruxolitinib may offer relief for skin-based graft-versus-host complications. If you are experiencing persistent skin symptoms post-transplant, speak with your care team about clinical trial options and newer topical treatment pathways.
Further reading
For more information on the latest developments in systemic and localized treatments, visit Cancer.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe developing topical alternatives to standard steroids is important for chronic disease management?
